Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

NCT00688558 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: JTT-705 600 mg and simvastatin 40 mg
DRUG: Placebo and simvastatin 40 mg

Sponsor

Akros Pharma Inc.